Document is current

Article History

Received: 10 August 2021

Accepted: 5 April 2022

First Online: 22 April 2022

Declarations

:

: Ethical approval was not applicable, but all methods were performed in accordance with relevant guidelines and regulations (e.g., good clinical practice).

: Not applicable.

: D.B. has received travel grants from AbbVie and Gilead Sciences; S.B. has received research grants from Gilead, and AbbVie; F.N. has received research grants, consultancy agreements and travel grants from UCB, Ipsen, Roche, Astellas, Ferring, Novartis, Janssen-Cilag, AbbVie, Gilead, CAF, Intercept, Gore, Bristol-Myers Squibb (BMS), MSD, Promethera Biosciences, Ono Pharma, Durect; H.R. has received research grants from Gilead, AbbVie and Pfizer; B.V.D. has received consultancy agreements for AbbVie, Gilead Sciences and MSD; T.V. is the recipient of a senior clinical research mandate from the FWO Flanders (18B2821N) and has participated in Advisory Committees or Review Panels for: Janssen Pharmaceuticals, Gilead Sciences, AbbVie, BMS, WL Gore. He has also received grant/research support from: Gilead Sciences, Roche, BMS and speaking and teaching support from: Gilead Sciences, BMS; G.R. has received research grants from AbbVie and Gilead Sciences, Janssen Pharmaceuticals, MSD, and consultancy agreements for AbbVie, BMS, Gilead Sciences and MSD. All other co-authors report no competing interests.